AllianceBernstein
CAPR icon

AllianceBernstein’s Capricor Therapeutics CAPR Stock Holding History

AllianceBernstein’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
40,430
+1,600
+4% +$42.6K ﹤0.01% 2271
2025
Q4 		$1.12M Sell
38,830
-39,890
-51% -$521K ﹤0.01% 2289
2025
Q3 		$568K Hold
78,720
– – ﹤0.01% 2615
2025
Q2 		$782K Buy
78,720
+65,440
+493% +$691K ﹤0.01% 2415
2025
Q1 		$126K Hold
13,280
– – ﹤0.01% 3028
2024
Q4 		$183K Buy
+13,280
New +$233K ﹤0.01% 3040
2015
Q4 		– Sell
-1,000
Closed -$41K – 2924
2015
Q3 		$41K Buy
+1,000
New +$44.5K ﹤0.01% 2919

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

AllianceBernstein's CAPR Position: Q1 2026 in Review

AllianceBernstein increased its Capricor Therapeutics (CAPR) stake by 4.1% in Q1 2026, buying an estimated $42.6K and bringing the position to 40,430 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

AllianceBernstein first reported a position in CAPR in Q3 2015 and has held it in 7 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • AllianceBernstein held 40,430 shares of Capricor Therapeutics worth $1.17M as of Q1 2026.
  • AllianceBernstein bought 1,600 Capricor Therapeutics shares in Q1 2026, an estimated $42.6K.
  • Capricor Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2271 holding.
  • AllianceBernstein first reported a position in Capricor Therapeutics in Q3 2015 and has held it in 7 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.